,2025 PHARMACOTHERAPEUTICS QUESTION
BANK: COMPREHENSIVE EXAM PREP
(ARCANGELO & PETERSON)
📘 Verified | Detailed Rationales | 1,120 Questions | Designed for Guaranteed Clinical
Competency
Table of Contents
1. Issues for the Practitioner in Drug Therapy
2. Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
3. Impact of Drug Interactions and Adverse Events on Therapeutics
4. Principles of Pharmacotherapy in Pediatrics, Pregnancy and Lactation
5. Pharmacotherapy Principles in Older Adults
6. Principles of Antimicrobial Therapy
7. Pharmacogenomics
8. The Economics of Pharmacotherapeutics
9. Principles of Pharmacology in Pain Management
10. Pain Management in Opioid Use Disorder (OUD) Patients
11. Cannabis and Pain Management
12. Dermatitis
13. Bacterial, Fungal, and Viral Infections of the Skin
14. Psoriasis
15. Acne Vulgaris and Rosacea
16. Ophthalmic Disorders
17. Otitis Media and Otitis Externa
18. Hypertension
19. Hyperlipidemia
20. Chronic Stable Angina and Myocardial Infarction
,21. Heart Failure
22. Arrhythmias
23. Respiratory Infections
24. Asthma and Chronic Obstructive Pulmonary Disease
25. Gastric, Functional and Inflammatory Bowel Disorders
26. Gastroesophageal Reflux Disease and Peptic Ulcer Disease
27. Liver Diseases
28. Urinary Tract Infection
29. Prostatic Disorders and Erectile Dysfunction
30. Overactive Bladder
31. Sexually Transmitted Infections
32. Osteoarthritis and Gout
33. Osteoporosis
34. Rheumatoid Arthritis
35. Headaches
36. Seizure Disorders
37. Alzheimer’s Disease
38. Parkinson Disease
39. Major Depressive Disorder and Bipolar Disorders
40. Anxiety Disorders
41. Sleep Disorders
42. Attention Deficit Hyperactivity Disorder
43. Substance Use Disorders
44. Diabetes Mellitus
45. Thyroid and Parathyroid Disorders
46. Allergies and Allergic Reactions
47. Human Immunodeficiency Virus
,48. Organ Transplantation
49. Pharmacotherapy for Select Thromboembolic Disorders
50. Anemias
51. Immunizations
52. Smoking Cessation
53. Weight Loss
54. Contraception
55. Menopause
56. Vaginitis
,1. An APP practicing in State X must check which of the
following before prescribing a Schedule II medication?
A. Federal DEA registration only
B. State X’s collaborative practice agreement and DEA
registration
C. Only the national guidelines for controlled substances
D. Manufacturer’s prescribing information
o Correct: B
o Rationale: APPs need both federal DEA registration
and state-specific collaborative practice authority.
Federal guidelines alone (C) or manufacturer info (D)
are insufficient; DEA only (A) ignores state scope.
2. Which statement best reflects ethical prescribing?
A. Prescribing the newest drug regardless of cost
B. Prioritizing patient welfare and minimizing harm
C. Always deferring to patient requests for branded
medications
D. Using industry samples to promote drugs
o Correct: B
o Rationale: Ethical prescribing balances benefit versus
harm. Newer drugs (A) may lack safety data; always
branded (C) can increase cost; samples (D) risk bias.
3. An elderly patient on five chronic medications is at risk of
polypharmacy. The APP’s best first action is to:
, A. Discontinue all non-essential medications immediately
B. Conduct a medication review to assess indication and
interactions
C. Switch all medications to once-daily formulations
D. Encourage over-the-counter supplements instead
o Correct: B
o Rationale: A thorough review identifies unnecessary
drugs and interactions. Immediate discontinuation (A)
is unsafe; dosing changes (C) don’t address need;
supplements (D) can worsen polypharmacy.
4. Which approach most effectively improves adherence in
a low-health-literacy patient?
A. Provide a multi-page printed drug guide
B. Use the teach-back method to confirm understanding
C. Ask the patient to read the prescription label aloud
D. Refer the patient to online resources
o Correct: B
o Rationale: Teach-back ensures comprehension. Long
guides (A) overwhelm; reading labels (C) assesses
literacy but not understanding; online resources (D)
may be inaccessible.
5. Before initiating therapy, an APP asks a patient about
cultural health beliefs. This exemplifies:
A. Informed consent
B. Shared decision-making
, C. Therapeutic inertia
D. Autonomy breach
o Correct: B
o Rationale: Eliciting beliefs engages patients in their
care. Informed consent (A) is part of but broader;
therapeutic inertia (C) is failure to act; autonomy
breach (D) is incorrect.
6. An APP declines a patient’s request for antibiotics for a
viral URI because:
A. Patient satisfaction scores outweigh guidelines
B. Antibiotics are ineffective and may cause harm
C. They dislike the patient’s demands
D. They never prescribe antibiotics
o Correct: B
o Rationale: Evidence-based practice avoids ineffective
and harmful treatment. Satisfaction (A) should not
override; personal dislike (C) is unethical; blanket
refusal (D) is inflexible.
7. Which action reflects provider accountability in
prescribing?
A. Delegating all medication decisions to nursing
B. Following up on lab results and adjusting doses
C. Assuming the pharmacy corrects any errors
D. Prescribing high-dose meds to shorten therapy
o Correct: B
, o Rationale: Accountability means monitoring and
adjusting therapy. Delegation (A) abdicates
responsibility; pharmacy (C) is last check; dose
escalation (D) may be unsafe.
8. An APP reviews two RCTs showing Drug A reduces stroke
risk. This is an example of:
A. Anecdotal evidence
B. Expert opinion
C. Level I evidence for decision-making
D. Basic pharmacokinetics
o Correct: C
o Rationale: RCTs represent top-level evidence.
Anecdote (A) and opinion (B) are lower;
pharmacokinetics (D) is unrelated.
9. To minimize cost and complexity, an APP consolidates
medication refills to a single monthly visit. This strategy
addresses:
A. Therapeutic duplication
B. Financial toxicity and adherence barriers
C. Adverse drug reaction reporting
D. Off-label prescribing
o Correct: B
o Rationale: Combined refills reduce travel/cost
burdens. Duplication (A) is a different issue; ADR
reporting (C) and off-label use (D) aren’t targeted.
,10. An APP discusses both risks and benefits of
chemotherapy with a non-English-speaking patient using
an interpreter. This demonstrates:
A. Cultural competence and informed consent
B. Polypharmacy avoidance
C. Ethical conflict
D. Regulatory compliance only
o Correct: A
o Rationale: Using an interpreter respects culture and
ensures consent. Polypharmacy (B) unrelated; not an
ethical conflict (C); goes beyond mere compliance (D).
11. Which documentation best supports APP
prescriptive authority?
A. Verbal note in chart
B. Signed collaborative practice agreement in the medical
record
C. Email from physician colleague
D. Patient’s acknowledgment
o Correct: B
o Rationale: A formal CPA is required by many states.
Verbal notes (A) lack legality; email (C) is informal;
patient acknowledgment (D) irrelevant.
12. A patient’s eGFR drops to 25 mL/min. The APP
should:
A. Continue current dose of renally cleared drug
, B. Consult renal dosing guidelines and adjust dose
C. Stop all meds immediately
D. Switch to drug with high renal clearance
o Correct: B
o Rationale: Renal dosing guidelines guide safe dosing.
Continuing unchanged (A) risks toxicity; stopping all
(C) may harm; switching to high-renal clearance (D)
worsens accumulation.
13. When encountering conflicting study results on a
drug’s efficacy, the APP should first:
A. Choose the more recent study only
B. Appraise study quality and applicability
C. Follow the first study found
D. Avoid prescribing until consensus emerges
o Correct: B
o Rationale: Critical appraisal balances methodology
and relevance. Recency (A) alone isn’t enough;
arbitrary selection (C) is poor; indefinite delay (D)
may harm if therapy indicated.
14. An APP notices a patient misunderstanding dosage
instructions. The best next step is to:
A. Yell instructions louder
B. Simplify language and confirm with teach-back
C. Hand over detailed printed instructions
D. Tell the patient to ask family members
BANK: COMPREHENSIVE EXAM PREP
(ARCANGELO & PETERSON)
📘 Verified | Detailed Rationales | 1,120 Questions | Designed for Guaranteed Clinical
Competency
Table of Contents
1. Issues for the Practitioner in Drug Therapy
2. Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
3. Impact of Drug Interactions and Adverse Events on Therapeutics
4. Principles of Pharmacotherapy in Pediatrics, Pregnancy and Lactation
5. Pharmacotherapy Principles in Older Adults
6. Principles of Antimicrobial Therapy
7. Pharmacogenomics
8. The Economics of Pharmacotherapeutics
9. Principles of Pharmacology in Pain Management
10. Pain Management in Opioid Use Disorder (OUD) Patients
11. Cannabis and Pain Management
12. Dermatitis
13. Bacterial, Fungal, and Viral Infections of the Skin
14. Psoriasis
15. Acne Vulgaris and Rosacea
16. Ophthalmic Disorders
17. Otitis Media and Otitis Externa
18. Hypertension
19. Hyperlipidemia
20. Chronic Stable Angina and Myocardial Infarction
,21. Heart Failure
22. Arrhythmias
23. Respiratory Infections
24. Asthma and Chronic Obstructive Pulmonary Disease
25. Gastric, Functional and Inflammatory Bowel Disorders
26. Gastroesophageal Reflux Disease and Peptic Ulcer Disease
27. Liver Diseases
28. Urinary Tract Infection
29. Prostatic Disorders and Erectile Dysfunction
30. Overactive Bladder
31. Sexually Transmitted Infections
32. Osteoarthritis and Gout
33. Osteoporosis
34. Rheumatoid Arthritis
35. Headaches
36. Seizure Disorders
37. Alzheimer’s Disease
38. Parkinson Disease
39. Major Depressive Disorder and Bipolar Disorders
40. Anxiety Disorders
41. Sleep Disorders
42. Attention Deficit Hyperactivity Disorder
43. Substance Use Disorders
44. Diabetes Mellitus
45. Thyroid and Parathyroid Disorders
46. Allergies and Allergic Reactions
47. Human Immunodeficiency Virus
,48. Organ Transplantation
49. Pharmacotherapy for Select Thromboembolic Disorders
50. Anemias
51. Immunizations
52. Smoking Cessation
53. Weight Loss
54. Contraception
55. Menopause
56. Vaginitis
,1. An APP practicing in State X must check which of the
following before prescribing a Schedule II medication?
A. Federal DEA registration only
B. State X’s collaborative practice agreement and DEA
registration
C. Only the national guidelines for controlled substances
D. Manufacturer’s prescribing information
o Correct: B
o Rationale: APPs need both federal DEA registration
and state-specific collaborative practice authority.
Federal guidelines alone (C) or manufacturer info (D)
are insufficient; DEA only (A) ignores state scope.
2. Which statement best reflects ethical prescribing?
A. Prescribing the newest drug regardless of cost
B. Prioritizing patient welfare and minimizing harm
C. Always deferring to patient requests for branded
medications
D. Using industry samples to promote drugs
o Correct: B
o Rationale: Ethical prescribing balances benefit versus
harm. Newer drugs (A) may lack safety data; always
branded (C) can increase cost; samples (D) risk bias.
3. An elderly patient on five chronic medications is at risk of
polypharmacy. The APP’s best first action is to:
, A. Discontinue all non-essential medications immediately
B. Conduct a medication review to assess indication and
interactions
C. Switch all medications to once-daily formulations
D. Encourage over-the-counter supplements instead
o Correct: B
o Rationale: A thorough review identifies unnecessary
drugs and interactions. Immediate discontinuation (A)
is unsafe; dosing changes (C) don’t address need;
supplements (D) can worsen polypharmacy.
4. Which approach most effectively improves adherence in
a low-health-literacy patient?
A. Provide a multi-page printed drug guide
B. Use the teach-back method to confirm understanding
C. Ask the patient to read the prescription label aloud
D. Refer the patient to online resources
o Correct: B
o Rationale: Teach-back ensures comprehension. Long
guides (A) overwhelm; reading labels (C) assesses
literacy but not understanding; online resources (D)
may be inaccessible.
5. Before initiating therapy, an APP asks a patient about
cultural health beliefs. This exemplifies:
A. Informed consent
B. Shared decision-making
, C. Therapeutic inertia
D. Autonomy breach
o Correct: B
o Rationale: Eliciting beliefs engages patients in their
care. Informed consent (A) is part of but broader;
therapeutic inertia (C) is failure to act; autonomy
breach (D) is incorrect.
6. An APP declines a patient’s request for antibiotics for a
viral URI because:
A. Patient satisfaction scores outweigh guidelines
B. Antibiotics are ineffective and may cause harm
C. They dislike the patient’s demands
D. They never prescribe antibiotics
o Correct: B
o Rationale: Evidence-based practice avoids ineffective
and harmful treatment. Satisfaction (A) should not
override; personal dislike (C) is unethical; blanket
refusal (D) is inflexible.
7. Which action reflects provider accountability in
prescribing?
A. Delegating all medication decisions to nursing
B. Following up on lab results and adjusting doses
C. Assuming the pharmacy corrects any errors
D. Prescribing high-dose meds to shorten therapy
o Correct: B
, o Rationale: Accountability means monitoring and
adjusting therapy. Delegation (A) abdicates
responsibility; pharmacy (C) is last check; dose
escalation (D) may be unsafe.
8. An APP reviews two RCTs showing Drug A reduces stroke
risk. This is an example of:
A. Anecdotal evidence
B. Expert opinion
C. Level I evidence for decision-making
D. Basic pharmacokinetics
o Correct: C
o Rationale: RCTs represent top-level evidence.
Anecdote (A) and opinion (B) are lower;
pharmacokinetics (D) is unrelated.
9. To minimize cost and complexity, an APP consolidates
medication refills to a single monthly visit. This strategy
addresses:
A. Therapeutic duplication
B. Financial toxicity and adherence barriers
C. Adverse drug reaction reporting
D. Off-label prescribing
o Correct: B
o Rationale: Combined refills reduce travel/cost
burdens. Duplication (A) is a different issue; ADR
reporting (C) and off-label use (D) aren’t targeted.
,10. An APP discusses both risks and benefits of
chemotherapy with a non-English-speaking patient using
an interpreter. This demonstrates:
A. Cultural competence and informed consent
B. Polypharmacy avoidance
C. Ethical conflict
D. Regulatory compliance only
o Correct: A
o Rationale: Using an interpreter respects culture and
ensures consent. Polypharmacy (B) unrelated; not an
ethical conflict (C); goes beyond mere compliance (D).
11. Which documentation best supports APP
prescriptive authority?
A. Verbal note in chart
B. Signed collaborative practice agreement in the medical
record
C. Email from physician colleague
D. Patient’s acknowledgment
o Correct: B
o Rationale: A formal CPA is required by many states.
Verbal notes (A) lack legality; email (C) is informal;
patient acknowledgment (D) irrelevant.
12. A patient’s eGFR drops to 25 mL/min. The APP
should:
A. Continue current dose of renally cleared drug
, B. Consult renal dosing guidelines and adjust dose
C. Stop all meds immediately
D. Switch to drug with high renal clearance
o Correct: B
o Rationale: Renal dosing guidelines guide safe dosing.
Continuing unchanged (A) risks toxicity; stopping all
(C) may harm; switching to high-renal clearance (D)
worsens accumulation.
13. When encountering conflicting study results on a
drug’s efficacy, the APP should first:
A. Choose the more recent study only
B. Appraise study quality and applicability
C. Follow the first study found
D. Avoid prescribing until consensus emerges
o Correct: B
o Rationale: Critical appraisal balances methodology
and relevance. Recency (A) alone isn’t enough;
arbitrary selection (C) is poor; indefinite delay (D)
may harm if therapy indicated.
14. An APP notices a patient misunderstanding dosage
instructions. The best next step is to:
A. Yell instructions louder
B. Simplify language and confirm with teach-back
C. Hand over detailed printed instructions
D. Tell the patient to ask family members
